Further in vitro experiments showed that ligustrazine might inhibit the progression of EMs by down-regulating UBOX5-AS1 to inhibit EMs cells invasion, induce apoptosis, and mediate the activation of MMP-9/TIMP-3 signaling (Hongfang et al., 2023). Here, MMP9 is linked to eosinophilia-myalgia syndrome.